CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.11
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company with businesses including CSL Behring, CSL Seqirus and CSL Vifor, focused on plasma therapies, vaccines and specialty medicines. Remove dated market-cap and return statistics.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$174.80

08 Sep
2026

1.620

OPEN

$172.04

0.94%

HIGH

$174.80

891,429

LOW

$171.38

TARGET
$165.959 -5.1% downside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 950.3 xxx
DPS (cps) 474.3 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 18.0 xxx
Dividend Yield 2.8% xxx
Div Pay Ratio(%) 49.9% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.49%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.36

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 10/03 - (franking ex-div 183.75c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-789.7
DPS All xxxxxxxxxxxxxxx405.4
Sales/Revenue xxxxxxxxxxxxxxx23,166.3 M
Book Value Per Share xxxxxxxxxxxxxxx4,459.7
Net Operating Cash Flow xxxxxxxxxxxxxxx5,182.8 M
Net Profit Margin xxxxxxxxxxxxxxx-16.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-14.97 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.37 %
Return on Assets xxxxxxxxxxxxxxx-7.00 %
Return on Equity xxxxxxxxxxxxxxx-14.97 %
Return on Total Capital xxxxxxxxxxxxxxx13.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2,145.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1,648 M
Long Term Debt xxxxxxxxxxxxxxx14,079 M
Total Debt xxxxxxxxxxxxxxx15,727 M
Goodwill - Gross xxxxxxxxxxxxxxx9,187 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,184 M
Price To Book Value xxxxxxxxxxxxxxx2.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx1,884.5 M
Capex % of Sales xxxxxxxxxxxxxxx8.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,113 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,134 M
Research & Development xxxxxxxxxxxxxxx1,805 M
Investments - Total xxxxxxxxxxxxxxx222 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

(xx/xx/xxxx)

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

02/09/2026

3

Neutral

$160.00

-8.47%

Citi highlights the US FDA has added a black box warning to CSL's Injectafer treatment due to the risk of serious symptomatic hypophosphatemia, or low phosphate levels.

Injectafer is CSL's high-dose intravenous iron treatment, marketed in the US by Daiichi Sankyo subsidiary American Regent.

The warning is not expected to materially change Injectafer's competitive position. The risk was already included in previous labelling and competing treatments also face safety warnings, the broker explains.

Neutral rated. Target $160.00.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

20/08/2026

2

Upgrade to Overweight from Neutral

$207.00

18.42%

Jarden upgrades CSL to Overweight from Neutral with its target price increased to $207.00 from $191.00 following an FY26 result that demonstrated better-than-expected operating profit across every division.

The analyst highlights that, although a step-up in sales force investment weighed on FY26 net profit after tax, constant currency performance landed marginally ahead of guidance.

The broker's estimates factor in restored confidence through FY27 guidance, which anticipates mid-single-digit growth for Behring and mid-to-high single-digit growth for immunoglobulin, easing prior fears regarding plasma collection.

Management expects low single-digit growth for Seqirus, whereas Vifor continues to face headwinds resulting in a projected -25% revenue decline for its portfolio in FY27.

The valuation is supported by a better overall growth outlook, cost-out initiatives, sales force reinvestment, and a US$1.1b share buyback.
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Australia Remains Outside The AI Party

10:00 AM - Rudi's View
2
August 2026 Results – The Wrap

Sep 08 2026 - Feature Stories
3
Australian Broker Call *Extra* Edition – Sep 07, 2026

Sep 07 2026 - Daily Market Reports
4
Rudi’s View: Resources, Healthcare & Best Buys

Sep 03 2026 - Rudi's View
5
August In Review: Much Better Than Feared

Sep 02 2026 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps